Biome Locks In Probiotical Supply to 2028 as Revenue Hits $12.4M

Biome Australia extended its exclusive supply agreement with Probiotical SpA through 2028. The announcement removes a contract expiry that would have landed in June 2026. No new financial conditions were disclosed; the extension operates on existing commercial terms. This is a narrow supply‑chain event with a broad footprint across Biome's international expansion, manufacturing onshoring program, and the clinical‑stage IP pipeline.

The simplest read is that management took a near‑term renegotiation risk off the table. The better read is that locking in Probiotical under an unchanged cost structure signals stable input pricing and a demand profile strong enough for the supplier to commit capacity. For a company posting 61.1% gross margins and positive EBITDA for eight consecutive quarters, holding that margin architecture through 2028 removes a variable that could have compressed the path to scale.

Probiotical has been the sole source of Biome's proprietary probiotic strains since incorporation in 2018. Founder and managing director Blair Vega Norfolk described the relationship in direct terms.

The 2026 Supply Expiry Is Now Off the Table

The previous agreement was set to end in under two years. A supplier change at that point would have competed for management attention just as Biome is activating distribution in Canada, the United Kingdom, Ireland, and New Zealand and beginning the capital commitment of manufacturing onshoring. Extending to 2028 aligns the supply horizon with the investment horizon of both projects.

By accepting existing commercial terms, Probiotical did not force a margin reset. If ingredient costs were under upward pressure or if Biome's volume commitments were weak, a two‑year renegotiation would have surfaced those tensions. The extension suggests neither condition is present. The result is that the profit‑and‑loss structure behind Biome's product portfolio stays fixed, while the binary risk of a supply transition is gone.

This is not the same as a gating event. It is a removal of an uncertainty that would have acted as a drag on valuation as the 2026 date approached. With the contract settled, capital market participants can focus on revenue execution rather than supply‑chain contingency.

International Distribution Without Frictional Costs

The supply continuity directly supports the company's distribution pipeline. Biome recently onboarded Fullscript Canada, expanding its presence in the practitioner‑channel market. It has added retail doors domestically and is building early‑stage presence in the UK, Ireland, and New Zealand.

In the probiotic segment, a clinical substantiation dossier is tied to specific strains. Changing the fermentation source can trigger equivalence testing, labelling changes, and re‑registration in each jurisdiction. For a company with $12.4 million in first‑half revenue, that kind of regulatory churn consumes cash flow best directed toward sales and marketing. Sticking with Probiotical eliminates those frictional costs across the markets the company is activating now. The supply agreement and the distribution build‑out are now on the same timeline.

Eight Quarters of EBITDA Consistency and 61.1% Gross Margin

Biome's financials provide the other half of the picture. First‑half FY2026 revenue was $12.4 million. Net profit reached $1.18 million. Gross margin held at 61.1%. The company has posted positive EBITDA for eight consecutive quarters.

A streak that long shifts the conversation from viability to scalability. Debt has been reduced and operating cash flow turned positive, which funds the onshoring and IP work without requiring dilutive capital raises at the small‑cap level. The margin consistency is a second‑order signal. When gross margin stays flat or rises alongside revenue expansion, the incremental sales are flowing to the bottom line. That dynamic, combined with a supply extension that locks the cost side, reduces execution risk on the company's 2028–2029 earnings trajectory.

A healthy small‑cap trading framework often flags this sequence: supply certainty, repeated EBITDA‑positive quarters, and stable margins are the prerequisites for re‑rating on forward multiples. Biome now checks those boxes.

BMB18 Trial Adds an IP Catalyst to the Supply Lock‑In

Beyond supply and distribution, the company is advancing intellectual property. A patent application has been filed for the proprietary probiotic strain BMB18. A human clinical trial is underway with La Trobe University. The Probiotical agreement covers the strain's supply, so the upstream manufacturing path for a BMB18‑branded product line is already in place.

A positive readout would allow Biome to pursue higher‑margin, clinically backed health claims. Combining a patent‑protected strain with an exclusive supply chain is the architecture that turns a distributor into a brand owner. The 2028 supply expiry gives the company a clear runway to commercialize BMB18 without supplier uncertainty overlapping the launch window.

The next concrete markers are patient enrollment completion, then top‑line data from the La Trobe trial. A positive result would validate the IP investment and turn the Probiotical relationship into an appreciating asset rather than a cost line. The supply extension announced today removes the contract overhang that could have complicated the build‑up to that catalyst.